05/01/2020
Urologie
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Future Oncol. 2020 Jun;16(16):1083-1189. doi: 10.2217/fon-2020-0056. Epub 2020 May 1.Future Oncol. 2020. PMID: 32356465dr. Uvin Pieterdr. Ghysel Christophe
10/01/2019
Urologie
106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer.
Annals of Oncology. 2019 Oct 1;30 (Supplement_5).dr. Ghysel Christophe
07/01/2019
Urologie
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
JAMA Oncol. 2019 Jul 1;5(7):1060–2.dr. Ghysel Christophe
05/01/2018
Oncologisch Centrum
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12. PMID: 29431193dr. Brouwers Barbaradr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
06/12/2023
Urologie
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Genome Medicine; 2018 Nov 16;:1–13.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
09/12/2018
Urologie
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.
Clinical Cancer Research. 2018 Sep 12;clincanres.1943.2018.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
05/01/2018
Urologie
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
Prostate. 2018 May;78(6):435–45.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
06/12/2023
Urologie
Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
Journal of Clinical Oncology. American Society of Clinical Oncology; 2017 May 20;35(15_suppl):5049–9.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel ChristopheUrologie
Project: Pro-Bio Trial, www.probiotrial.org ProBio (‘Prostate Biomarkers’) is an adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven phase 3 trial in men with CRPC. Men (n=750) will be randomized to receive either standard of care (following national guidelines) or treatment with Enzalutamide, Abiraterone, Docetaxel, Cabazitaxel, or Carboplatin, based on a liquid biopsy profile.
2020-01-01dr. Ghysel ChristopheUrologie
106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer.
Barcelonadr. Ghysel ChristopheUrologie
Comprehensive AR profiling and genomic characterization of castration-resistant prostate cancer in the context of endocrine therapy using circulating tumour cells and cell-free DNA.
Stockholm, Swedendr. Ghysel ChristopheUrologie
Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer.
Chicago, USAdr. Ghysel ChristopheUrologie
Detection of AR perturbations in circulating tumour cells and cell-free DNA from patients with metastatic castration-resistant prostate cancer predicts resistance to endocrine therapy.
Oostendedr. Ghysel ChristopheUrologie
Comprehensive AR profiling and genomic characterization of castration-resistant prostate cancer in the context of endocrine therapy using circulating tumour cells and cell-free DNA.
Luikdr. Ghysel ChristopheUrologie
Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer.
Brusseldr. Ghysel ChristopheUrologie
Detection of aberrant androgen receptor transcripts in circulating tumour cells as a predictor of resistance to AR directed treatment in patients with castration resistant prostate cancer.
Brusseldr. Ghysel ChristopheUrologie